NCT07682519 Multimodal Telerehabilitation Versus Face-to-Face Care for Adults With Hemophilia and Chronic Pain
| NCT ID | NCT07682519 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Chile |
| Condition | Hemophilia |
| Study Type | INTERVENTIONAL |
| Enrollment | 24 participants |
| Start Date | 2026-07-02 |
| Primary Completion | 2027-01-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 24 participants in total. It began in 2026-07-02 with a primary completion date of 2027-01-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Hemophilia is an inherited bleeding disorder that is commonly associated with chronic joint pain, reduced physical function, and decreased quality of life. Pain science education combined with exercise therapy has shown beneficial effects in people with chronic musculoskeletal pain; however, its effectiveness in people with hemophilia remains largely unknown. Telerehabilitation may improve access to rehabilitation by reducing geographical and transportation barriers, but its effectiveness compared with face-to-face delivery has not been established in this population. This randomized controlled non-inferiority trial will compare a 6-week multimodal telerehabilitation program consisting of pain science education and therapeutic exercise with an equivalent face-to-face program in adults with hemophilia and chronic pain. Participants will be randomly assigned to one of the two interventions. Clinical outcomes will be assessed before and after the intervention by an assessor blinded to group allocation. The study aims to determine whether telerehabilitation provides clinical outcomes that are not inferior to those achieved with conventional face-to-face rehabilitation.
Eligibility Criteria
Inclusion Criteria: Male adults aged 18 to 60 years. Diagnosis of hemophilia A or hemophilia B. Chronic pain, defined as pain occurring every day for at least 3 months or on at least half of the days during the previous 6 months. Pain involving the elbow, knee, or ankle. Receiving prophylactic clotting factor replacement therapy at least three times per week. Current medical referral for physical therapy. Residence in the Metropolitan Region of Chile. Ability to understand study procedures and provide written informed consent. Exclusion Criteria: Inability to understand study instructions or provide informed consent. Neurological disorders affecting the central nervous system (e.g., stroke). Current participation in alternative therapies for pain management. Previous participation in a pain neuroscience education program. Orthopedic surgery or major musculoskeletal trauma within the previous 12 months.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07682519 clinical trial?
This trial is open to male participants only, aged 18 Years or older, up to 60 Years, studying Hemophilia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07682519 currently recruiting?
Yes, NCT07682519 is actively recruiting participants. Contact the research team at r_nunez@uchile.cl for enrollment information.
Where is the NCT07682519 trial being conducted?
This trial is being conducted at Santiago, Chile.
Who is sponsoring the NCT07682519 clinical trial?
NCT07682519 is sponsored by University of Chile. The trial plans to enroll 24 participants.